Johns Hopkins Cancer Center | Strategic Alliance Partners

April 10, 2021

Neoadjuvant treatment with nivolumab combined with chemotherapy led to a significant improvement in pathologic complete response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

March 18, 2021

Benjamin P. Levy, MD, discusses the importance of testing for KRAS mutations in lung cancer.

March 11, 2021

Dr. Levy discusses key research efforts with targeted therapies for patients with lung cancer who harbor NTRK, KRAS, and HER2 aberrations.

February 10, 2021

Julie R. Brahmer, MD, discusses emerging targeted therapies for patients with lung cancer who harbor EGFR exon 20 insertion mutations.

February 05, 2021

Although advances in diagnosis and treatment have led to improvements in overall survival for patients with NSCLC, low rates of survival outcomes are present even in those with nonmetastatic disease.

December 09, 2020

Jerry L​e Pow Spivak, MD, discusses diagnosing essential thrombocythemia.